Kh. Grotemeyer et al., Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study, J NEUR SCI, 181(1-2), 2000, pp. 65-72
Piracetam has been shown to inhibit platelet aggregation. Therefore, we per
formed a double-blind, randomized, parallel group study to compare the effi
cacy of daily 1600 mg piracetam t.i.d. vs. 200 mg acetylsalicylic acid (ASA
) t.i.d. in secondary stroke prophylaxis. 563 patients after stroke as conf
irmed by computed tomography (CT) or magnetic resonance imaging (MRI) were
enrolled and received either piracetam or ASA during a 2 year follow-up per
iod. The primary endpoint was the rate of stroke, transient ischaemic attac
k (TIA), or death from vascular cause. The secondary endpoint was the rate
of adverse events leading to a premature discontinuation of the study medic
ation. Patients were visited at home every 3 months and were examined in ho
spital after 1 and 2 years. At every visit, the platelet function was evalu
ated. No significant difference and no significant equivalence could be sho
wn for the primary endpoint between the piracetam and the ASA group both in
the intention-to-treat and in the per-protocol analysis. However, there wa
s a not significant trend in favor of ASA (11.7 vs. 15.2%). After excluding
those patients who did not respond to antiplatelet medication in vitro, ho
wever, piracetam and ASA were equivalent in secondary stroke prophylaxis (s
troke, TIA, or vascular death 10.1% in the piracetam group vs. 9.7% in the
ASA group) Piracetam was significantly superior to ASA in the secondary end
point (P = 0.0039). The data suggest that the overall efficacy of piracetam
in secondary stroke prophylaxis is not as good as that of ASA but that pir
acetam is better tolerated. However, our data furthermore show that nonresp
onders to pharmacological inhibition of platelet function are more frequent
under piracetam therapy and that they may influence the results of large s
tudies: on secondary prophylaxis in vascular diseases. (C) 2000 Elsevier Sc
ience B.V. All rights reserved.